["{\n\"step_by_step_thinking\": \"The question is about a study assessing the antileukemic activity of a new tyrosine kinase inhibitor in patients with chronic myeloid leukemia in blast crisis. The study is described as having successive dose cohorts, where patients are assigned to each dose and treatment efficacy is determined by complete blood counts and bone marrow assessments. This suggests that the study is an open-labeled clinical trial, where patients know what they're receiving.\",\n\"answer_choice\": \"C\"\n}"]